AVXL · Anavex Life Sciences Corp. · Insider Trading

As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025.

As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025.

As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025.

As described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 28, 2026, the election of the Issuer's board of directors at the Issuer's 2026 Annual Meeting of Stockholders on September 24, 2026 constituted a "change in control" under the Issuer's incentive plans and Ms. Boenisch's employment agreement and all outstanding and unvested awards previously granted to Ms. Boenisch became immediately vested and exercisable in accordance with the terms of the applicable incentive plan and award agreement under which they were granted, including the following awards which had not been previously reported due to their performance-based vesting terms: 20,000 options at an exercise price of $10.09 granted June 27, 2022, 25,000 options at an exercise price of $8.57 granted March 31, 2023, 25,000 options at an exercise price of $5.36 granted February 20, 2024 and 25,000 options at an exercise price of $8.58 granted March 31, 2025.

On March 31, 2025, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was a second regulatory dialogue for blarcamesine. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares.

On March 31, 2025, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was a Second Regulatory dialogue for blarcamesine. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.

On February 20, 2024, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Readout of AV3-71-SZ-001 schizophrenia study. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.

On February 20, 2024, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Readout of AV3-71-SZ-001 schizophrenia study. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares.

Represents a "net exercise" of outstanding stock options, which options were scheduled to expire on September 18, 2025. The reporting person received 42,452 shares of common stock on net exercise of an option to purchase 187,500 shares of common stock. The Company withheld 145,048 shares of common stock underlying the option as consideration for the exercise price and tax withholdings, using the closing price on September 11, 2025 of $9.58, pursuant to the terms of the Company's 2015 Stock Option Plan.

On March 31, 2025, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of preclinical blarcamesine prevention AD data. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares.

On March 31, 2025, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of preclinical blarcamesine prevention AD data. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.

Represents a "net exercise" of outstanding stock options, which options were scheduled to expire on June 15, 2025. The reporting person received 38,651 shares of common stock on net exercise of an option to purchase 50,000 shares of common stock. The Company withheld 11,349 shares of common stock underlying the option as consideration for the exercise price, using the average of the high and low sales price on June 5, 2025 of $7.75, pursuant to the terms of the Company's 2007 Stock Option Plan.

The options vested in three equal annual installments beginning on June 15, 2016

On March 31, 2023, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was completion of enrollment of ANAVEX3-71 Phase 2 clinical trial in Schizophrenia. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.

On March 31, 2023, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was completion of enrollment of ANAVEX3-71 Phase 2 clinical trial in Schizophrenia. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares.

The option vests in three equal annual installments beginning on March 31, 2026

The option vests in three equal annual installments beginning on March 31, 2026

The option vests in three equal annual installments beginning on March 31, 2026

The option vests in three equal annual installments beginning on March 31, 2026

The option vests in three equal annual installments beginning on March 31, 2026

Represents a "net exercise" of outstanding stock options, which options were scheduled to expire on April 2, 2025. The reporting person received 217,503 shares of common stock on net exercise of an option to purchase 500,000 shares of common stock. The Company withheld 282,497 shares of common stock underlying the option as consideration for the exercise price and tax withholdings, using the average of the high and low sales price on March 24, 2025 of $9.63, pursuant to the terms of the Company's 2007 Stock Option Plan.

On March 31, 2023, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of AD-004 Alzheimer's disease study. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.

On June 14, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in three equal tranches based on performance milestones, one of which was completion of Phase 2b/3 study for Alzheimer's disease. The performance criteria for this milestone was met with the final publication of all clinical trial data, resulting in vesting of the option as to 166,000 shares.

On March 31, 2023, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was Publication of AD-004 Alzheimer's disease study. The performance criteria for this milestone was met, resulting in vesting of the option as to 12,500 shares.

On February 20, 2024, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was regulatory submission of AD-004 for Alzheimer's disease (US or EU). The performance criteria for this milestone was met with the acceptance of the MAA filing by the EMA, resulting in vesting of the option as to 125,000 shares.

On February 20, 2024, the reporting person was granted an option to purchase 50,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which was regulatory submission of AD-004 for Alzheimer's disease (US or EU). The performance criteria for this milestone was met with the acceptance of the MAA filing by the EMA, resulting in vesting of the option as to 12,500 shares.

On June 27, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included completion of the Clinical Study Report for Phase 2a/b AD-004 Alzheimer's disease study. The performance criteria for this milestone was met in connection with the Marketing Authorization Application filing, resulting in vesting of the option as to 125,000 shares.

On June 27, 2022, the reporting person was granted an option to purchase 40,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included completion of the Clinical Study Report for Phase 2a/b AD-004 Alzheimer's disease study. The performance criteria for this milestone was met in connection with the Marketing Authorization Application filing, resulting in vesting of the option as to 10,000 shares.

Purchase price denominated in Euros has been translated to US dollars using an exchange rate of 0.936

Purchase price denominated in Euros has been translated to US dollars using an exchange rate of 0.92

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.03 to $5.195, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Options vest in equal installments over three years from the grant date.

Options vest in equal installments over three years from the grant date.

Options vest in equal installments over three years from the grant date.

Options vest in equal installments over three years from the grant date.

Options vest in equal installments over three years from the grant date.

On June 27, 2022, the reporting person was granted an option to purchase 40,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included topline data readout of ANAVEX2-73-RS-003 EXCELLENCE clinical trial in Rett Syndrome. The performance criteria for this milestone was met, resulting in vesting of the option as to 10,000 shares.

On June 27, 2022, the reporting person was granted an option to purchase 500,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included topline data readout of ANAVEX2-73-RS-003 EXCELLENCE clinical trial in Rett Syndrome. The performance criteria for this milestone was met, resulting in vesting of the option as to 125,000 shares.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.95 to $8.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.